十九酰氯 | 59410-47-8

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酰卤化物
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 中文名称: 十九酰氯
• 英文名称: nonadecanoyl chloride
• CAS: 59410-47-8
• 化学式: C₁₉H₃₇ClO
• 分子量: 316.955
• InChiKey: BASNZTUXPUAQLZ-UHFFFAOYSA-N

物化性质

• 沸点：
  359.1±5.0 °C(Predicted)
• 密度：
  0.903±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  21
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.947
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  8
• WGK Germany：
  3
• 海关编码：
  2915900090
• 包装等级：
  III
• 危险品运输编号：
  UN 3265 8/PG 3

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Nonadecanoyl chloride
CAS-No. : 59410-47-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C19H37ClO
Molecular Weight : 316,95 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Store under inert gas. Moisture sensitive.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 3265 IMDG: 3265 IATA: 3265
UN proper shipping name
ADR/RID: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S. (Nonadecanoyl chloride)
IMDG: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S. (Nonadecanoyl chloride)
IATA: Corrosive liquid, acidic, organic, n.o.s. (Nonadecanoyl chloride)
Transport hazard class(es)
ADR/RID: 8 IMDG: 8 IATA: 8
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  十九酰氯 在 1,4-二氧六环 、 氨 作用下， 生成 十九烷酰胺
  参考文献：
  名称：

  Cason et al., Journal of Organic Chemistry, 1949, vol. 14, p. 153

  摘要：

  DOI：
• 作为产物：
  描述：

  十九烷酸 在 草酰氯 作用下， 生成 十九酰氯
  参考文献：
  名称：

  结构，超分子组织和相行为的ň酰基-β-丙氨酸：哺乳动物大脑成分的结构同源ñ -acylglycine和ñ酰基氨基丁酸

  摘要：

  Ñ酰基-β-丙氨酸（一个Nabas）是结构同源物Ñ -acylglycines（唠叨）和Ñ酰基-γ氨基酸（NAGABAs），和非手性异构体Ñ -acylalanines，这些都是存在于哺乳动物的脑和其他组织和调节具有各种功能的生物受体的活性。在本研究中，我们合成并表征了一系列带有饱和酰基链的NABA（n = 8-20），并研究了它们的超分子组织和热致相行为。在差示扫描量热（DSC）研究中，大多数NABA在干态主链熔融相变之前以及与水水合时都会发生一两个次要的过渡，但在与缓冲液水合时仅会发生一个过渡（ pH 7.6）。从DSC研究获得的跃迁焓（ΔH t）和熵（ΔS t）显示出在干燥状态和缓冲液水合时对链长的线性依赖性，而在用水水合时观察到奇偶变化。N-月桂酰-β-丙氨酸（NLBA）和N的晶体结构在P21 / c空间群的单斜系统中解决了-肉豆蔻酰基-β-丙氨酸（NMBA）问题。NLBA和NMB

  DOI：

  10.1016/j.chemphyslip.2016.10.002

文献信息

• Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides
  申请人：ELI LILLY AND COMPANY

  公开号：EP0825164A2

  公开（公告）日：1998-02-25

  This invention relates to a novel solution phase process for the preparation of amide, carbamate, and sulfonamide combinatorial libraries. These libraries have utility for drug discovery and are used to form wellplate components of novel assay kits.

  这项发明涉及一种用于制备酰胺、碳酸酯和磺酰胺组合库的新型溶液相过程。这些库在药物发现中具有实用价值，并用于形成新型检测套件的微孔板组件。
• [EN] ALPHA HELIX MIMETICS AND METHODS RELATING THERETO<br/>[FR] MIMÉTIQUES D'HÉLICE ALPHA ET PROCÉDÉS S'Y RAPPORTANT
  申请人：PRISM BIOLAB CORP

  公开号：WO2012115286A1

  公开（公告）日：2012-08-30

  Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a compound relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

  α-螺旋拟态结构和由式(I)表示的化合物，其中一般式和每个符号的定义如规范中所定义，涉及的化合物以及涉及的方法被披露。还披露了这些化合物在治疗医疗状况（例如癌症疾病、纤维化疾病）中的应用，以及包含这些拟态体的药物组合物。
• Glycosyl-Substituted Dicarboxylates as Detergents for the Extraction, Overstabilization, and Crystallization of Membrane Proteins
  作者：Kim-Anh Nguyen、Marine Peuchmaur、Sandrine Magnard、Romain Haudecoeur、Cédric Boyère、Saravanan Mounien、Ikram Benammar、Veronica Zampieri、Sébastien Igonet、Vincent Chaptal、Anass Jawhari、Ahcène Boumendjel、Pierre Falson

  DOI：10.1002/anie.201713395

  日期：2018.3.5

  To tackle the problems associated with membrane protein (MP) instability in detergent solutions, we designed a series of glycosyl‐substituted dicarboxylate detergents (DCODs) in which we optimized the polar head to clamp the membrane domain by including, on one side, two carboxyl groups that form salt bridges with basic residues abundant at the membrane–cytoplasm interface of MPs and, on the other

  为了解决清洁剂溶液中与膜蛋白（MP）不稳定性相关的问题，我们设计了一系列糖基取代的二羧酸盐清洁剂（DCOD），其中我们优化了极性头，通过在一侧包含两个羧基来夹持膜结构域。形成盐桥的基团具有大量残留在MPs的膜-细胞质界面上的碱性残基，另一方面是形成氢键的糖。经萃取，将DCODs图8b，图8c和9b中保存BMRA，一个ATP结合盒泵的ATP酶的功能，更有效地比参考或最近设计的洗涤剂。所述DCODs 8，图8b，图8f，9，和9 b引起BmRA的热位移为20至29°C，天然形式的G蛋白偶联腺苷受体A 2A R的热位移为13至21°C 。化合物8 f和8 g改善了BmRA晶体的衍射分辨率从6到4Å。因此，DCOD被认为是MP的结构生物学的有前途和强大的工具。
• Synthesis of a-O- and a-S-Glycosphingolipids Related to Sphingomonous cell Wall Antigens Using Anomerisation
  作者：Wayne Pilgrim、Ciaran O'Reilly、Paul Murphy

  DOI：10.3390/molecules180911198

  日期：——

  Analogues of glycolipids from Spingomonadacaece with O- and S- and SO2-linkages have been prepared using chelation induced anomerisation promoted by TiCl4. Included are examples of the anomerisation of intermediates with O- and S-glycosidic linkages as well as isomerisation of β-thioglycuronic acids (β-glycosyl thiols). The β-O-glucuronide and β-O-galacturonide precursors were efficiently prepared using benzoylated trichloroacetimidates. β-Glycosyl thiols were precursors to β-S-derivatives. Triazole containing mimics of the natural glycolipids were prepared using CuI promoted azide-alkyne cycloaddition reactions in THF. The glycolipid antigens are being evaluated currently for their effects on iNKT cells.

  来自Spingomonadacaece的糖脂类类似物，具有O-、S-和SO2-连接，通过TiCl4催化的螯合诱导的异构化进行了制备。其中包括具有O-和S-糖苷键的中间体异构化的例子，以及β-硫葡萄糖醇酸（β-糖苷硫醇）的异构化。β-O-葡萄糖醛酸酯和β-O-半乳糖醛酸酯的前体采用苯甲酰化三氯乙酰胺高效制备。β-糖苷硫醇是β-S-衍生物的前体。含有三唑的天然糖脂类模仿物使用CuI催化的叠氮烷炔环加成反应在THF中制备。当前正在评估这些糖脂抗原对iNKT细胞的影响。
• 抗菌活性を有するカルノサジンラクタム誘導体
  申请人：塩野義製薬株式会社

  公开号：JP2016027001A

  公开（公告）日：2016-02-18

  【課題】従来の抗菌剤に比べて改善された特性を有する新規化合物、それを含有する医薬組成物の提供。【解決手段】式（Ｉ）：[式中、Ｒ1は、水素原子、アルキル、アルケニル、アルキニル、アルキルカルボニル、アルケニルカルボニルなどであり、Ｒ2は、水素原子、アルキル、アルケニル、アルキニル、シクロアルキル、シクロアルケニル、アルキルカルボニルなどであり、Ｒ3は、水素原子、アルキル、アルケニル、アルキニルまたは−Ｃ（ＮＨＲ31）＝ＮＲ32であり、Ｒ31は、水素原子、アルキル、アルケニル、アルキニル、アルキルカルボニル、アルケニルカルボニル、アルキニルカルボニル、アルキルオキシカルボニル、アルケニルオキシカルボニルまたはアルキニルオキシカルボニルであり、Ｒ32は、水素原子、アルキル、アルケニルまたはアルキニルである。］で示される化合物またはその製薬上許容される塩。【選択図】なし

  提供具有改进特性的新化合物，该化合物包含在医药组合物中。公式（I）：[其中，R1为氢原子，烷基，烯基，炔基，烷基羰基，烯基羰基等；R2为氢原子，烷基，烯基，炔基，环烷基，环烯基，烷基羰基等；R3为氢原子，烷基，烯基，炔基或-C（NH-R31）=NR32，R31为氢原子，烷基，烯基，炔基，烷基羰基，烯基羰基，炔基羰基，烷氧羰基，烯氧羰基或炔氧羰基，R32为氢原子，烷基，烯基或炔基。]所示的化合物或其在制药上可容许的盐。【选择图】无